Organogenesis Holdings (ORGO) Income from Continuing Operations (2016 - 2026)

Organogenesis Holdings' Income from Continuing Operations history runs 11 years deep, the most recent figure standing at 53156000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 182.1% year-over-year to 53156000.0 in Q1 2026; TTM through Mar 2026 was 8124000.0, a 151.15% increase from a year earlier, with the FY2025 full-year figure at 42437000.0, up 4828.8% from the prior year.
• Income from Continuing Operations eased to 53156000.0 in Q1 2026 per ORGO's latest filing, from 49105000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 49105000.0 in Q4 2025 and bottomed at 53156000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 1444000.0 (2023), against an average of 743058.82.
• Across the five-year window, Income from Continuing Operations jumped 1373.02% in 2023 and plunged 797.29% in 2025, its largest moves.
• Year by year, Income from Continuing Operations stood at 7486000.0 in 2022, then sank by 80.71% to 1444000.0 in 2023, then jumped by 431.37% to 7673000.0 in 2024, then surged by 539.97% to 49105000.0 in 2025, then slumped by 208.25% to 53156000.0 in 2026.
• Per Business Quant, the three latest ORGO Income from Continuing Operations figures stand at 53156000.0 (Q1 2026), 49105000.0 (Q4 2025), and 21567000.0 (Q3 2025).